

References

1. Vesikari T, Langley JM, Segall N, Ward BJ, Cooper C, Poliquin G, Smith B, Gantt S, McElhaney JE, Dionne M, van Damme P, Leroux-Roels I, Leroux-Roels G, Machluf N, Spaans JN, Yassin-Rajkumar B, Anderson DE, Popovic V, Diaz-Mitoma F; PROTECT Study Group. Immunogenicity and Safety of a Tri-antigenic versus a Mono-antigenic Hepatitis B Vaccine in Adults (PROTECT): A randomized, double-blind, phase 3 trial. *Lancet Infect Dis*. 2021 September;21(9):1271-1281.
2. Elhanan E, Boaz M, Schwartz I, Schwartz D, Chernin G, Soetendorp H, Gal Oz A, Agbaria A, Weinstein T. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B®, among vaccine naïve and vaccine non-responder dialysis patients. *Clin Exp Nephrol*. 2018 Feb;22(1):151-158.
3. Chow KM, Lo SH, Szeto CC, Yuen SK, Wong KS, Kwan BC, Leung CB, Li PK. Extra-high-dose hepatitis B vaccination does not confer longer serological protection in peritoneal dialysis patients: a randomized controlled trial. *Nephrol Dial Transplant*. 2010 Jul;25(7):2303-9.
4. Canadian Immunization Guide: Hepatitis B Vaccine. Updated May 2022. Accessed September 2022. <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-7-hepatitis-b-vaccine.html>
5. Vesikari T, Finn A, van Damme P, et al. Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial. *JAMA Netw Open*. 2021 October;4(10)
6. Walayat S, Ahmed Z, Martin D, Puli S, Cashman M, Dhillon S. Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. *World J Hepatol*. 2015 Oct 28;7(24):2503-9.